Associations - Tagrisso (osimertinib)

EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
EGFR G719X	Non Small Cell Lung Cancer	EGFR G719X	Non Small Cell Lung Cancer	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2
EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2
EGFR L861Q	Non Small Cell Lung Cancer	EGFR L861Q	Non Small Cell Lung Cancer	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2
EGFR S768I	Non Small Cell Lung Cancer	EGFR S768I	Non Small Cell Lung Cancer	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2
EGFR exon 19 deletion + EGFR T790M	Non Small Cell Lung Cancer	EGFR exon 19 deletion + EGFR T790M	Non Small Cell Lung Cancer	osimertinib Resistant: A2 - Guideline osimertinib Resistant : A2	osimertinib Resistant: A2 - Guideline osimertinib Resistant : A2
EGFR T790M	Lung Non-Squamous Non-Small Cell Cancer	EGFR T790M	Lung Non-Squamous Non-Small Cell Cancer	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2
EGFR L858R	Lung Non-Squamous Non-Small Cell Cancer	EGFR L858R	Lung Non-Squamous Non-Small Cell Cancer	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2
EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer	EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	osimertinib Sensitive: B - Late Trials osimertinib Sensitive : B	osimertinib Sensitive: B - Late Trials osimertinib Sensitive : B
EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	osimertinib + afatinib Sensitive: B - Late Trials osimertinib + afatinib Sensitive : B	osimertinib + afatinib Sensitive: B - Late Trials osimertinib + afatinib Sensitive : B
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	bevacizumab + osimertinib Sensitive: B - Late Trials bevacizumab + osimertinib Sensitive : B	bevacizumab + osimertinib Sensitive: B - Late Trials bevacizumab + osimertinib Sensitive : B
EGFR mutation	Lung Cancer	EGFR mutation	Lung Cancer	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1
EGFR exon 19 deletion	Lung Adenocarcinoma	EGFR exon 19 deletion	Lung Adenocarcinoma	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1
EGFR T790M	Lung Adenocarcinoma	EGFR T790M	Lung Adenocarcinoma	osimertinib Resistant: C1 - Off-label osimertinib Resistant : C1	osimertinib Resistant: C1 - Off-label osimertinib Resistant : C1
EGFR L858R	Lung Adenocarcinoma	EGFR L858R	Lung Adenocarcinoma	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1
EGFR exon 19 deletion	Small Cell Lung Cancer	EGFR exon 19 deletion	Small Cell Lung Cancer	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1
EGFR T790M	Lung Cancer	EGFR T790M	Lung Cancer	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1
EGFR L858R	Lung Cancer	EGFR L858R	Lung Cancer	osimertinib Resistant: C1 - Off-label osimertinib Resistant : C1	osimertinib Resistant: C1 - Off-label osimertinib Resistant : C1
EGFR T790M	Small Cell Lung Cancer	EGFR T790M	Small Cell Lung Cancer	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	bevacizumab + osimertinib Sensitive: C2 – Inclusion Criteria bevacizumab + osimertinib Sensitive : C2	bevacizumab + osimertinib Sensitive: C2 – Inclusion Criteria bevacizumab + osimertinib Sensitive : C2
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	osimertinib + ABT 263 Sensitive: C2 – Inclusion Criteria osimertinib + ABT 263 Sensitive : C2	osimertinib + ABT 263 Sensitive: C2 – Inclusion Criteria osimertinib + ABT 263 Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	osimertinib + ramucirumab Sensitive: C2 – Inclusion Criteria osimertinib + ramucirumab Sensitive : C2	osimertinib + ramucirumab Sensitive: C2 – Inclusion Criteria osimertinib + ramucirumab Sensitive : C2
EGFR mutation	Lung Cancer	EGFR mutation	Lung Cancer	bevacizumab + osimertinib Sensitive: C2 – Inclusion Criteria bevacizumab + osimertinib Sensitive : C2	bevacizumab + osimertinib Sensitive: C2 – Inclusion Criteria bevacizumab + osimertinib Sensitive : C2
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	osimertinib + gefitinib Sensitive: C2 – Inclusion Criteria osimertinib + gefitinib Sensitive : C2	osimertinib + gefitinib Sensitive: C2 – Inclusion Criteria osimertinib + gefitinib Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	osimertinib + ABT 263 Sensitive: C2 – Inclusion Criteria osimertinib + ABT 263 Sensitive : C2	osimertinib + ABT 263 Sensitive: C2 – Inclusion Criteria osimertinib + ABT 263 Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	osimertinib + gefitinib Sensitive: C2 – Inclusion Criteria osimertinib + gefitinib Sensitive : C2	osimertinib + gefitinib Sensitive: C2 – Inclusion Criteria osimertinib + gefitinib Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib + savolitinib Sensitive: C2 – Inclusion Criteria osimertinib + savolitinib Sensitive : C2	osimertinib + savolitinib Sensitive: C2 – Inclusion Criteria osimertinib + savolitinib Sensitive : C2

Tagrisso (osimertinib)

Associations
(301)

Associations
(301)

Tagrisso (osimertinib)

Associations(301)

Associations(301)

Associations
(301)

Associations
(301)